Literature DB >> 29400708

Predictive immune biomarkers: an unattainable chimera?

Anna Maria Trotta1, Roberto Pacelli2, Stefania Scala3.   

Abstract

Year:  2018        PMID: 29400708      PMCID: PMC6141568          DOI: 10.1038/cmi.2017.162

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN: 1672-7681            Impact factor:   11.530


× No keyword cloud information.
  13 in total

Review 1.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.

Authors:  Padmanee Sharma; Siwen Hu-Lieskovan; Jennifer A Wargo; Antoni Ribas
Journal:  Cell       Date:  2017-02-09       Impact factor: 41.582

2.  Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade.

Authors:  Spencer C Wei; Jacob H Levine; Alexandria P Cogdill; Yang Zhao; Nana-Ama A S Anang; Miles C Andrews; Padmanee Sharma; Jing Wang; Jennifer A Wargo; Dana Pe'er; James P Allison
Journal:  Cell       Date:  2017-08-10       Impact factor: 41.582

3.  Targeted therapy: ARIEL3 - broad benefit of PARP inhibitors in ovarian cancer.

Authors:  David Killock
Journal:  Nat Rev Clin Oncol       Date:  2017-10-10       Impact factor: 66.675

4.  First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication.

Authors:  Steven Lemery; Patricia Keegan; Richard Pazdur
Journal:  N Engl J Med       Date:  2017-10-12       Impact factor: 91.245

5.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

Authors:  Dung T Le; Jennifer N Uram; Hao Wang; Bjarne R Bartlett; Holly Kemberling; Aleksandra D Eyring; Andrew D Skora; Brandon S Luber; Nilofer S Azad; Dan Laheru; Barbara Biedrzycki; Ross C Donehower; Atif Zaheer; George A Fisher; Todd S Crocenzi; James J Lee; Steven M Duffy; Richard M Goldberg; Albert de la Chapelle; Minori Koshiji; Feriyl Bhaijee; Thomas Huebner; Ralph H Hruban; Laura D Wood; Nathan Cuka; Drew M Pardoll; Nickolas Papadopoulos; Kenneth W Kinzler; Shibin Zhou; Toby C Cornish; Janis M Taube; Robert A Anders; James R Eshleman; Bert Vogelstein; Luis A Diaz
Journal:  N Engl J Med       Date:  2015-05-30       Impact factor: 91.245

6.  Systemic Immunity Is Required for Effective Cancer Immunotherapy.

Authors:  Matthew H Spitzer; Yaron Carmi; Nathan E Reticker-Flynn; Serena S Kwek; Deepthi Madhireddy; Maria M Martins; Pier Federico Gherardini; Tyler R Prestwood; Jonathan Chabon; Sean C Bendall; Lawrence Fong; Garry P Nolan; Edgar G Engleman
Journal:  Cell       Date:  2017-01-19       Impact factor: 41.582

7.  The Challenge for Development of Valuable Immuno-oncology Biomarkers.

Authors:  Janice M Mehnert; Arta M Monjazeb; Johanna M T Beerthuijzen; Deborah Collyar; Larry Rubinstein; Lyndsay N Harris
Journal:  Clin Cancer Res       Date:  2017-09-01       Impact factor: 12.531

8.  Classification of Advanced Human Cancers Based on Tumor Immunity in the MicroEnvironment (TIME) for Cancer Immunotherapy.

Authors:  Yu Zhang; Lieping Chen
Journal:  JAMA Oncol       Date:  2016-11-01       Impact factor: 31.777

9.  PD-1 blockade induces responses by inhibiting adaptive immune resistance.

Authors:  Paul C Tumeh; Christina L Harview; Jennifer H Yearley; I Peter Shintaku; Emma J M Taylor; Lidia Robert; Bartosz Chmielowski; Marko Spasic; Gina Henry; Voicu Ciobanu; Alisha N West; Manuel Carmona; Christine Kivork; Elizabeth Seja; Grace Cherry; Antonio J Gutierrez; Tristan R Grogan; Christine Mateus; Gorana Tomasic; John A Glaspy; Ryan O Emerson; Harlan Robins; Robert H Pierce; David A Elashoff; Caroline Robert; Antoni Ribas
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

10.  Predictors of responses to immune checkpoint blockade in advanced melanoma.

Authors:  N Jacquelot; M P Roberti; D P Enot; S Rusakiewicz; N Ternès; S Jegou; D M Woods; A L Sodré; M Hansen; Y Meirow; M Sade-Feldman; A Burra; S S Kwek; C Flament; M Messaoudene; C P M Duong; L Chen; B S Kwon; A C Anderson; V K Kuchroo; B Weide; F Aubin; C Borg; S Dalle; O Beatrix; M Ayyoub; B Balme; G Tomasic; A M Di Giacomo; M Maio; D Schadendorf; I Melero; B Dréno; A Khammari; R Dummer; M Levesque; Y Koguchi; L Fong; M Lotem; M Baniyash; H Schmidt; I M Svane; G Kroemer; A Marabelle; S Michiels; A Cavalcanti; M J Smyth; J S Weber; A M Eggermont; L Zitvogel
Journal:  Nat Commun       Date:  2017-09-19       Impact factor: 14.919

View more
  4 in total

1.  Technical advances in NK cell-based cellular immunotherapy.

Authors:  Fang Fang; Wei Wang; Minhua Chen; Zhigang Tian; Weihua Xiao
Journal:  Cancer Biol Med       Date:  2019-11       Impact factor: 4.248

Review 2.  Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy.

Authors:  Cai Zhang; Yuxia Liu
Journal:  Front Immunol       Date:  2020-06-23       Impact factor: 7.561

Review 3.  Decoding cancer's camouflage: epithelial-mesenchymal plasticity in resistance to immune checkpoint blockade.

Authors:  Maria L Lotsberg; Austin Rayford; Jean Paul Thiery; Giuliana Belleggia; Stacey D'Mello Peters; James B Lorens; Salem Chouaib; Stephane Terry; Agnete S T Engelsen
Journal:  Cancer Drug Resist       Date:  2020-10-12

Review 4.  Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma.

Authors:  Jun Zhang; L Jeffrey Medeiros; Ken H Young
Journal:  Front Oncol       Date:  2018-09-10       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.